Updated Monday, 9/11. Five issuers are currently scheduled to list in the week ahead, although one is too small for our IPO stats. Small issuers may also join the calendar during the week. Chip designer Arm (ARM) is set to price its...read more
Vitro Biopharma, a Phase 1-ready biotech developing stem cell therapies for various indications, announced terms for its IPO on Thursday. In its latest filing, the company also disclosed financials for the six months ended April 30, 2023. The Denver, CO-based...read more
Vitro Biopharma, a Phase 1-ready biotech developing stem cell therapies for various indications, filed on Friday with the SEC to raise up to $17 million in an initial public offering. Vitro Biopharma is developing novel cellular therapies derived from...read more
US IPO Week Ahead: Arm set to test the IPO market with biggest listing in nearly two years
Updated Monday, 9/11. Five issuers are currently scheduled to list in the week ahead, although one is too small for our IPO stats. Small issuers may also join the calendar during the week. Chip designer Arm (ARM) is set to price its...read more
US IPO Week Ahead: Small deals slip through the IPO window as annual August lull sets in
The IPO market’s annual August lull is here, and with no notable launches this past week, we likely won’t see any major deals until...read more
Stem cell biotech Vitro Biopharma sets terms for $10 million IPO
Vitro Biopharma, a Phase 1-ready biotech developing stem cell therapies for various indications, announced terms for its IPO on Thursday. In its latest filing, the company also disclosed financials for the six months ended April 30, 2023. The Denver, CO-based...read more
Stem cell biotech Vitro Biopharma files for a $17 million IPO
Vitro Biopharma, a Phase 1-ready biotech developing stem cell therapies for various indications, filed on Friday with the SEC to raise up to $17 million in an initial public offering. Vitro Biopharma is developing novel cellular therapies derived from...read more